{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T13:03:59Z","timestamp":1772456639847,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This study was funded by Eisai Inc., Woodcliff Lake, NJ"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prior pooled analysis of eribulin studies (301 and 305) indicated eribulin prolonged overall survival (OS) in patients with locally advanced\/metastatic breast cancer (MBC) regardless of visceral or nonvisceral disease. This hypothesis-generating post hoc analysis examined the efficacy of eribulin according to the location of metastatic sites at baseline in 1864 pretreated patients with locally advanced\/MBC from studies 301 and 305. Analyses included OS, progression-free survival (PFS), and objective response rate; OS and PFS were also analyzed according to estrogen-receptor status. Eribulin appeared efficacious in patients with locally advanced\/MBC, irrespective of the location of metastases at baseline. A nominally significant difference in OS in favor of patients randomized to eribulin compared with control in patients with bone, lymph node, and chest wall\/breast\/skin metastases at baseline was observed. Additionally, a difference in OS was also seen in patients with liver metastases randomized to eribulin versus control (median: 13.4 versus 11.3 months, respectively; hazard ratio, 0.84 [95% CI: 0.72, 0.97]). Results of this exploratory analysis suggest that eribulin may be efficacious for the treatment of locally advanced\/MBC for patients with bone, liver, lung, lymph node, and chest wall\/breast\/skin metastases.<\/jats:p>","DOI":"10.1038\/s41598-020-66980-0","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T10:03:03Z","timestamp":1594202583000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis"],"prefix":"10.1038","volume":"10","author":[{"given":"Joyce","family":"O\u2019Shaughnessy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Twelves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori J.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karenza","family":"Alexis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-667X","authenticated-orcid":false,"given":"Carlos","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9080-9377","authenticated-orcid":false,"given":"Takayuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,8]]},"reference":[{"key":"66980_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3109\/02841869109092375","volume":"30","author":"C Kamby","year":"1991","unstructured":"Kamby, C. et al. Pattern of spread and progression in relation to the characteristics of the primary tumour in human breast cancer. Acta Oncol. 30, 301\u2013308 (1991).","journal-title":"Acta Oncol."},{"key":"66980_CR2","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/bjc.2015.127","volume":"112","author":"DJ Lobbezoo","year":"2015","unstructured":"Lobbezoo, D. J. et al. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? Br. J. Cancer 112, 1445\u20131451 (2015).","journal-title":"Br. J. Cancer"},{"key":"66980_CR3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.breast.2012.03.003","volume":"21","author":"F Cardoso","year":"2012","unstructured":"Cardoso, F. et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 21, 242\u2013252 (2012).","journal-title":"Breast"},{"key":"66980_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/cncr.11083","volume":"97","author":"J Chang","year":"2003","unstructured":"Chang, J. et al. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97, 545\u2013553 (2003).","journal-title":"Cancer"},{"key":"66980_CR5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s10549-015-3352-0","volume":"150","author":"CD Savci-Heijink","year":"2015","unstructured":"Savci-Heijink, C. D. et al. Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res. Treat. 150, 547\u2013557 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"66980_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.rpor.2013.01.001","volume":"18","author":"A Khanfir","year":"2013","unstructured":"Khanfir, A. et al. Prognostic factors and survival in metastatic breast cancer: A single institution experience. Rep. Pract. Oncol. Radiother. 18, 127\u2013132 (2013).","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"66980_CR7","first-page":"1013","volume":"61","author":"MJ Towle","year":"2001","unstructured":"Towle, M. J. et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 61, 1013\u20131021 (2001).","journal-title":"Cancer Res."},{"key":"66980_CR8","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","volume":"4","author":"MA Jordan","year":"2005","unstructured":"Jordan, M. A. et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther. 4, 1086\u20131095 (2005).","journal-title":"Mol. Cancer Ther."},{"key":"66980_CR9","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1158\/1535-7163.MCT-08-0095","volume":"7","author":"T Okouneva","year":"2008","unstructured":"Okouneva, T., Azarenko, O., Wilson, L., Littlefield, B. A. & Jordan, M. A. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol. Cancer Ther. 7, 2003\u20132011 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"66980_CR10","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1021\/bi901810u","volume":"49","author":"JA Smith","year":"2010","unstructured":"Smith, J. A. et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 49, 1331\u20131337 (2010).","journal-title":"Biochemistry"},{"key":"66980_CR11","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-14-3252","volume":"21","author":"NF Dybdal-Hargreaves","year":"2015","unstructured":"Dybdal-Hargreaves, N. F., Risinger, A. L. & Mooberry, S. L. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin. Cancer Res. 21, 2445\u20132452 (2015).","journal-title":"Clin. Cancer Res."},{"key":"66980_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/2045-824X-6-3","volume":"6","author":"SI Agoulnik","year":"2014","unstructured":"Agoulnik, S. I. et al. Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro. Vasc. Cell 6, 3 (2014).","journal-title":"Vasc. Cell"},{"key":"66980_CR13","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/cas.12488","volume":"105","author":"Y Funahashi","year":"2014","unstructured":"Funahashi, Y. et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 105, 1334\u20131342 (2014).","journal-title":"Cancer Sci."},{"key":"66980_CR14","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/bjc.2014.80","volume":"110","author":"T Yoshida","year":"2014","unstructured":"Yoshida, T. et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br. J. Cancer 110, 1497\u20131505 (2014).","journal-title":"Br. J. Cancer"},{"key":"66980_CR15","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/bjc.2016.122","volume":"114","author":"S Ueda","year":"2016","unstructured":"Ueda, S. et al. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab. Br. J. Cancer 114, 1212\u20131218 (2016).","journal-title":"Br. J. Cancer"},{"key":"66980_CR16","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes, J. et al. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377, 914\u2013923 (2011).","journal-title":"Lancet"},{"key":"66980_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2019.02.002","volume":"112","author":"P Yuan","year":"2019","unstructured":"Yuan, P. et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. Eur. J. Cancer 112, 57\u201365 (2019).","journal-title":"Eur. J. Cancer"},{"key":"66980_CR18","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman, P. A. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 33, 594\u2013601 (2015).","journal-title":"J. Clin. Oncol."},{"key":"66980_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","volume":"148","author":"C Twelves","year":"2014","unstructured":"Twelves, C. et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res. Treat. 148, 553\u2013561 (2014).","journal-title":"Breast Cancer Res. Treat."},{"key":"66980_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205\u2013216 (2000).","journal-title":"J. Natl. Cancer Inst."},{"key":"66980_CR21","first-page":"7","volume":"1","author":"B Y\u00fccel","year":"2014","unstructured":"Y\u00fccel, B. et al. Importance of metastasis site in survival of patients with breast cancer. Austin J. Med. Oncol. 1, 7 (2014).","journal-title":"Austin J. Med. Oncol."},{"key":"66980_CR22","doi-asserted-by":"publisher","first-page":"5971","DOI":"10.1158\/1078-0432.CCR-16-0460","volume":"22","author":"P Brodt","year":"2016","unstructured":"Brodt, P. Role of the microenvironment in liver metastasis: From pre- to prometastatic niches. Clin. Cancer Res. 22, 5971\u20135982 (2016).","journal-title":"Clin. Cancer Res."},{"key":"66980_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ctrv.2018.08.008","volume":"70","author":"J Cortes","year":"2018","unstructured":"Cortes, J., Sch\u00f6ffski, P. & Littlefield, B. A. Multiple modes of action of eribulin mesylate: emerging data and clinical implications. Cancer Treat. Rev. 70, 190\u2013198 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"66980_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0657-1","volume":"17","author":"C Twelves","year":"2015","unstructured":"Twelves, C. et al. \u201cNew\u201d metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Res 17, 150 (2015).","journal-title":"Breast Cancer Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66980-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66980-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66980-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T13:08:39Z","timestamp":1670332119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66980-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["66980"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-66980-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,8]]},"assertion":[{"value":"19 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Joyce O\u2019Shaughnessy: <i>Financial<\/i>: Honoraria from Seattle Genetics. Speaking fees from Blue Earth Diagnostics, and Novartis. Vendor-sponsored travel from AstraZeneca, Blue Earth Diagnostics, Eli-Lilly, Merck, Novartis, and Seattle Genetics. Consultant\/advisory role for AstraZeneca, Celgene, Eli-Lilly, LaRoche, Lilly USA, Merck, Novartis, and Pfizer. <i>Nonfinancial<\/i>: Nothing to disclose. Javier Cortes: <i>Financial<\/i>: Consulting\/Advisor for Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, and Merck Sharp & Dohme. Honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung, Lilly, and Merck Sharp & Dohme. Research funding (to the Institution) from Roche, Ariad Pharmaceuticals, AstraZeneca, Baxalta GMBH\/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffman-La Roche, Guardant Health, Merck Sharp & Dohme, Pfizer, Piqur Therapeutics, Puma C, Queen Mary University of London, and Seagen. Stock, patents, and intellectual property with MedSIR. <i>Nonfinancial:<\/i> Nothing to disclose. Chris Twelves: <i>Financial:<\/i> Personal fees and costs of clinical trials from Eisai during the conduct of the study. Personal fees and costs related to attending academic meetings from Pfizer; personal fees and costs related to clinical trials from Nektar; costs related to attending academic meetings from Roche\/Genentech; and costs related to meeting attendance from Amcure, all outside the submitted work. <i>Nonfinancial:<\/i> Eisai. Lori J. Goldstein: <i>Financial<\/i>: Consultant\/advisor for Merck, Genentech, Syndax, Immunomedics, Aduro, Genomic Health, Amgen, and Mylan; research support for Merck and Genentech; CME lecture for Genomic Health and Teva; DSMB for Daiichi Sankyo. <i>Nonfinancial:<\/i> Patient education for the Komen Foundation. Karenza Alexis: <i>Financial<\/i>: Former employee of Eisai Inc. <i>Nonfinancial:<\/i> Nothing to disclose. Ran Xie: <i>Financial<\/i>: Current employee of Eisai Inc. <i>Nonfinancial:<\/i> Nothing to disclose. Carlos Barrios: <i>Financial<\/i>: Clinical research support from AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Celgene, Covance, Lilly, Medivation, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, PharmaMar, and Roche\/Genentech. Advisory board and consulting fees from Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche\/Genentech, and Eisai. <i>Nonfinancial:<\/i> Nothing to disclose. Takayuki Ueno: <i>Financial<\/i>: Personal fees from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., AstraZeneca K.K., Taiho Pharmaceutical Co., Ltd., and Novartis Pharma K.K., outside the submitted work. <i>Nonfinancial<\/i>: Nothing to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11203"}}